Lung Cancer? What Patients Need to Know about Immunotherapy

In this webinar designed for patients and caregivers, Leena Gandhi, M.D., Ph.D., discussed current immunotherapy treatment options for patients with lung cancer, and the latest breakthroughs that paved the way for immunotherapy to help even more patients.

Leena Gandhi, M.D., Ph.D., is the Director of Thoracic Medical Oncology at New York University’s Langone Medical Center and an Associate Professor of Medicine at NYU’s Laura and Isaac Perlmutter Cancer Center. Her work, which has mostly dealt with lung cancer, has investigated the use of checkpoint inhibitors for lung cancer patients. She was the lead investigator on a pivotal phase 1 clinical trial that showed the usefulness of using PD-L1 as a biomarker for patients receiving anti-PD-L1 checkpoint immunotherapy. These biomarker efforts aim to enable doctors to better predict which patients will benefit from immunotherapy, and furthermore, to allow them to better monitor patients undergoing immunotherapy to determine how they’re responding. Together, these should provide doctors with tools that can improve immunotherapy’s ability to help improve the survival of lung cancer patients.

This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This series is presented by Genentech and LabAnswer and its employees, with generous support from Abbvie, Celldex Therapeutics, NewLink Genetics, and Regeneron. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.